Successful outcome using rituximab as the only immunomodulation in Henoch-Schonlein purpura: case report

E. Pillebout, F. Rocha, L. Fardet, M. Rybojad, J. Verine, D. Glotz
2011 Nephrology, Dialysis and Transplantation  
2. Higgins R, Ramaiyan K, Dasgupta T et al. Hyponatremia and hyperkalemia are more frequent in renal transplant recipients treated with tracrolimus than with cyclosporine. Further evidence for differences between cyclosporine and tacrolimus nephrotoxicities. Nephrol Dial Transplant 2004; 19: 444-450 3. Azuma T, Narumi H, Kojima K et al. Hyponatremia during administration of tacrolimus in an allogenic bone marrow transplant recipient. Int J Hematol 2003; 78: 268-269 4. Rabb HA, Niles JL, Cosimi
more » ... , Niles JL, Cosimi AB et al. Severe hyponatremia associated with combined pancreatic and renal transplantation. Transplantation 1989; 48: 157-159 5. Heering P, Ivens K, Aker S et al. Distal tubular acidosis induced by FK506. Clin Transplant 1998; 12: 465-471 6. Aker S, Heering P, Kinne-Saffran E et al. Different effects of cyclosporine and FK506 on potassium transport systems in MDCK cells. Abstract In the current report, we describe a patient with moderate nephritis and severe skin Henoch Schönlein purpura (HSP) who has been treated with rituximab. Complete and sustained skin and renal remission resulted from the treatment. Thus, further studies are required to confirm the efficacy of rituximab as first-line treatment in HSP, and it might be an interesting new therapeutic option.
doi:10.1093/ndt/gfr137 pmid:21436378 fatcat:6sifmz35k5cplda6kyfktgtlm4